Skip to main content
SpringerLink
Log in

Phase I Trial of Dose-Dense Docetaxel and Doxorubicin with or without Sargramostim in Patients with Metastatic Breast Cancer

  • Short Communication
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective ran- domized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17: 1413–24

    PubMed  CAS  Google Scholar 

  2. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194–201

    Article  PubMed  CAS  Google Scholar 

  3. Nabholtz JM, Pienkowski T, Mackey JPM, et al. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study [abstract no. 141]. Proc Am Soc Clin Oncol 2002; 21: 36a

    Google Scholar 

  4. Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87: 1210–5

    Article  PubMed  CAS  Google Scholar 

  5. O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812–23

    Article  PubMed  Google Scholar 

  6. Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEI CAM-9903) phase III study. J Clin Oncol 2004; 22: 2587–93

    Article  PubMed  CAS  Google Scholar 

  7. Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in meta-static breast cancer. Br J Cancer 2004; 91 (8): 1466–71

    PubMed  CAS  Google Scholar 

  8. Mackey J, Paterson A, Dirix LY, et al. Final Results of the Phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer [abstract no. 137]. Proc Am Soc Clin Oncol 2002; 21: 35a

    Google Scholar 

  9. Nabholtz JM, Paterson A, Dirix J, et al. A phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer [abstract no. 83]. Proc Am Soc Clin Oncol 2001; 20: 22a

    Google Scholar 

  10. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21: 968–75

    Article  PubMed  CAS  Google Scholar 

  11. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707–15

    PubMed  CAS  Google Scholar 

  12. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20: 3114–21

    Article  PubMed  CAS  Google Scholar 

  13. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21: 1431–9

    Article  PubMed  CAS  Google Scholar 

  14. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47: 207–14.

    Article  PubMed  CAS  Google Scholar 

  15. Sparano JA, O’Neill A, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 2000; 18: 2369–77

    PubMed  CAS  Google Scholar 

  16. von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19: 3506–15

    Google Scholar 

  17. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10: 553–60

    Article  PubMed  CAS  Google Scholar 

  18. Schwartz J, Domchek SM, Hwang WT, et al. Evaluation of anemia, neutropenia and skin toxicities in standard o dosedense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 2005; 16 (2): 247–52

    Article  PubMed  CAS  Google Scholar 

  19. Jackisch C, von Minckwitz G, Eidtmann H, et al. Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer. 2002; 3: 276–80

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Funding for this study was provided by Sanofi-Aventis and Immunex. The authors have no potential conflicts of interest that are directly relevant to the contents of this article.

Author information

Authors and Affiliations

  1. Department of Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, Texas, 77230-1439, USA

    Alberto Montero, Daniel Booser, Laura Esparza-Guerra, James Murray, Marguerite Rosales, Gabriel Hortobagyi &  Vicente Valero

Authors
  1. Alberto Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Booser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Esparza-Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marguerite Rosales
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriel Hortobagyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vicente Valero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vicente Valero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montero, A., Booser, D., Esparza-Guerra, L. et al. Phase I Trial of Dose-Dense Docetaxel and Doxorubicin with or without Sargramostim in Patients with Metastatic Breast Cancer. Drugs R D 6, 299–305 (2005). https://doi.org/10.2165/00126839-200506050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200506050-00006

Keywords

Search

Navigation